Clinical Scorecard: Diffuse Large B-Cell Lymphoma Manifesting as a Scalp Lesion with Skull Erosion and Neurological Symptoms: A Case Study

At a Glance

Key Highlights

• Rare presentation of DLBCL with extensive skull destruction and CNS involvement.
• Histopathological examination revealed non-GCB phenotype of DLBCL.
• Imaging studies indicated multi-organ involvement and significant osteolytic skull destruction.
• Treatment included Pola-R-CHP and CNS-directed therapy with high-dose methotrexate.
• Marked regression of the tumor and improvement of neurological symptoms observed post-treatment.

Guideline-Based Recommendations

Diagnosis

• Early biopsy and systemic evaluation of cutaneous lesions are essential.

Management

• Initiate systemic chemotherapy with Pola-R-CHP for high-risk DLBCL.

Monitoring & Follow-up

• Monitor soluble IL-2 receptor levels and neurological symptoms during treatment.

Risks

• Potential for aggressive systemic disease indicated by cutaneous lesions.

Patient & Prescribing Data

High-risk DLBCL patients with IPI score ≥2.

Pola-R-CHP demonstrated improved progression-free survival compared to R-CHOP.

Clinical Best Practices

• Conduct thorough differential diagnosis for rapidly enlarging scalp tumors.
• Utilize imaging studies to assess for CNS involvement in suspected cases.
• Consider RANKL expression in tumor cells as a potential factor in osteolytic features.

Related Resources & Content

• POLARIX trial